Article

Discovery of an Antiviral PROTAC Targeting the SARS-CoV-2 Main Protease Using an Allosteric Warhead

2025-05-07

Abstract excerpt

<h4>ABSTRACT</h4> Targeted protein degradation represents a new paradigm in drug development. By hijacking the cellular ubiquitin-proteasome-system pathogenic proteins are degraded via heterobifunctional molecules, referred to as proteolysis targeting chimeras (PROTACs). However, to date, only few PROTACs targeting viral or proviral proteins have been developed. To explore the possibilities and advantages of anti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bcb04113-bd57-52fe-9fdd-c857b8ac185a
DOI: 10.1101/2025.05.03.652023

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of an Antiviral PROTAC Targeting the SARS-CoV-2 Main Protease Using an Allosteric WarheadDOI 10.1101/2025.05.03.652023Read

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main ProteaseSemantic proximity Read

Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an M <sup>pro</sup> Protease Inhibitor for Treatment of SARS-CoV-2Semantic proximity Read

Targeted protein degraders of SARS-CoV-2 Mpro demonstrate superior antiviral activity over enzymatic inhibition alone and potency against nirmatrelvir resistant virusSemantic proximity Read

PROTACs: great opportunities for academia and industrySemantic proximity Read

PROTAC’ing oncoproteins: targeted protein degradation for cancer therapySemantic proximity Read

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19Semantic proximity Read

New-generation advanced PROTACs as potential therapeutic agents in cancer therapySemantic proximity Read

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitorsSemantic proximity Read

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read

bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)Semantic proximity Read

Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningSemantic proximity Read

Inhibition mechanism and antiviral activity of an α-ketoamide based SARS-CoV-2 main protease inhibitorSemantic proximity Read